Biotechnology Companies By Net Asset

LargestBiggest EarnersMost ProfitableMost LiquidHighly LeveragedTop DividendsCapital-HeavyHighest ValuationLargest Workforce
Net Asset
Return On Equity
Return On Asset
Profit Margin
Operating Margin
Current Valuation
Shares Outstanding
Shares Owned By Insiders
Shares Owned By Institutions
Number Of Shares Shorted
Price To Earning
Price To Book
Price To Sales
Revenue
Gross Profit
EBITDA
Net Income
Cash And Equivalents
Cash Per Share
Total Debt
Debt To Equity
Current Ratio
Book Value Per Share
Cash Flow From Operations
Short Ratio
Earnings Per Share
Price To Earnings To Growth
Target Price
Number Of Employees
Beta
Market Capitalization
Total Asset
Retained Earnings
Working Capital
Current Asset
Current Liabilities
Net AssetEfficiencyMarket RiskExp Return
1ALDX Aldeyra
104.61 T
 0.14 
 4.67 
 0.63 
2OTLK OUTLOOK THERAPEUTICS INC
28.82 T
 0.04 
 5.57 
 0.25 
3MLTX MoonLake Immunotherapeutics
477.93 B
(0.14)
 2.85 
(0.39)
4ZYME Zymeworks Common Stock
463.09 B
(0.04)
 3.26 
(0.14)
5ABBV AbbVie Inc
135.16 B
 0.22 
 1.30 
 0.29 
6INO Inovio Pharmaceuticals
113.2 B
 0.05 
 4.71 
 0.22 
7AMGN Amgen Inc
91.84 B
 0.22 
 1.48 
 0.32 
8GILD Gilead Sciences
58.99 B
 0.16 
 1.58 
 0.25 
9GMAB Genmab AS
45.81 B
(0.02)
 2.75 
(0.04)
10COYA Coya Therapeutics, Common
44.35 B
 0.11 
 4.07 
 0.46 
11REGN Regeneron Pharmaceuticals
37.76 B
(0.06)
 2.00 
(0.11)
12NERV Minerva Neurosciences
37.14 B
(0.04)
 4.27 
(0.18)
13HLN Haleon plc
34.31 B
 0.07 
 1.42 
 0.10 
14BIIB Biogen Inc
28.05 B
(0.05)
 1.70 
(0.08)
15VRTX Vertex Pharmaceuticals
22.53 B
 0.25 
 1.47 
 0.37 
16BNTX BioNTech SE
22.53 B
(0.08)
 3.15 
(0.24)
17GRFS Grifols SA ADR
21.44 B
 0.02 
 2.74 
 0.06 
18QNRX Quoin Pharmaceuticals Ltd
15.71 B
(0.08)
 7.69 
(0.60)
19MRNA Moderna
14.14 B
(0.03)
 5.26 
(0.18)
20GLYC GlycoMimetics
11.09 B
 0.09 
 5.80 
 0.50 
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund. Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY